GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forward Pharma A/S (OTCPK:FWPAY) » Definitions » EV-to-EBITDA

Forward Pharma A/S (Forward Pharma A/S) EV-to-EBITDA : 20.64 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Forward Pharma A/S EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Forward Pharma A/S's enterprise value is $-52.39 Mil. Forward Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.54 Mil. Therefore, Forward Pharma A/S's EV-to-EBITDA for today is 20.64.

The historical rank and industry rank for Forward Pharma A/S's EV-to-EBITDA or its related term are showing as below:

FWPAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.06   Med: 0.06   Max: 20.64
Current: 20.64

During the past 11 years, the highest EV-to-EBITDA of Forward Pharma A/S was 20.64. The lowest was -0.06. And the median was 0.06.

FWPAY's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.79 vs FWPAY: 20.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Forward Pharma A/S's stock price is $400.50. Forward Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-28.410. Therefore, Forward Pharma A/S's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Forward Pharma A/S EV-to-EBITDA Historical Data

The historical data trend for Forward Pharma A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forward Pharma A/S EV-to-EBITDA Chart

Forward Pharma A/S Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 3.70 6.35 9.05 7.45

Forward Pharma A/S Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.05 - 7.45 -

Competitive Comparison of Forward Pharma A/S's EV-to-EBITDA

For the Biotechnology subindustry, Forward Pharma A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forward Pharma A/S's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forward Pharma A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Forward Pharma A/S's EV-to-EBITDA falls into.



Forward Pharma A/S EV-to-EBITDA Calculation

Forward Pharma A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-52.390/-2.538
=20.64

Forward Pharma A/S's current Enterprise Value is $-52.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Forward Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forward Pharma A/S  (OTCPK:FWPAY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Forward Pharma A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=400.50/-28.410
=At Loss

Forward Pharma A/S's share price for today is $400.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Forward Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-28.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Forward Pharma A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Forward Pharma A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Forward Pharma A/S (Forward Pharma A/S) Business Description

Traded in Other Exchanges
N/A
Address
Ostergade 24A, 1st Floor, Copenhagen, DNK, 1100
Forward Pharma A/S is a biopharmaceutical company that engages in the research and production of medicinal treatments for multiple sclerosis and psoriasis.